The utility of pharmacokineticpharmacodynamic modeling in the discovery and optimization of selective S1P1 agonists

Xenobiotica

Volumn 42, Issue 7, 2012, Pages 671-686

  Taylor, Simon ^a   Gray, James R J ^a   Willis, Robert ^a   Deeks, Nigel ^a   Haynes, Andrea ^a   Campbell, Colin ^a   Gaskin, Pam ^a   Leavens, Karen ^a   Demont, Emmanuel ^a   Dowell, Simon ^a   Cryan, Jenni ^a   Morse, Mary ^a   Patel, Aarti ^a   Garden, Helen ^a   Witherington, Jason ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Allometric scaling; Drug discovery; in vitroin vivo potency correlation; Indirect response model; Lymphopenia; PKPD; S1P1

Indexed keywords

BETA ARRESTIN; FINGOLIMOD; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOMODULATING AGENT; SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST; UNCLASSIFIED DRUG; DRUG DERIVATIVE; LYSOPHOSPHOLIPID; PROPANEDIOL DERIVATIVE; RETINA S ANTIGEN; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1-PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; RAT; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; MULTIPLE SCLEROSIS; RAT STRAIN; SIGNAL TRANSDUCTION;

RATTUS;

ANIMALS; ARRESTIN; GTP-BINDING PROTEINS; LYMPHOCYTES; LYSOPHOSPHOLIPIDS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; RATS; RATS, INBRED STRAINS; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84861905290     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.645908     Document Type: Article

References (28)

1. Albert R, Hinterding K, Brinkmann V, Guerini D, Müller-Hartwieg C, Knecht H, Simeon C, Streiff M, Wagner T, Welzenbach K, Zécri F, Zollinger M, Cooke N, Francotte E. (2005). Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J Med Chem 48:5373-5377.
2. Bayliss MK, Bell JA, Jenner WN, Wilson K. (1990). Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. Biochem Soc Trans 18:1198-1199.
3. Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N, Baumruker T. (2003). Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 278:47408-47415.
4. Bolli MH, Lescop C, Nayler O. (2011). Synthetic sphingosine 1-phosphate receptor modulators-opportunities and potential pitfalls. Curr Top Med Chem 11:726-757.
5. Budde K, Schütz M, Glander P, Peters H, Waiser J, Liefeldt L, Neumayer HH, Böhler T. (2006). FTY720 (fingolimod) in renal transplantation. Clin Transplant 20 17:17-24.
6. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
7. Demont E, Andrews B, Bit R, Campbell C, Cooke J, Deeks N, Desai S, Dowell S, Gaskin, P, Gray J, Haynes A, Holmes D, Kumar H, Morse M, Osborne G, Panchal T, Patel B, Perboni A, Taylor S, Watson R, Witherington J, Willis R. (2011). Discovery of a selective S1P1 receptor agonist efficacious at low oral dose and devoid of effects on heart rate. ACS Med Chem Lett 2:444-449.
8. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, Mills S, Nomura N, Rosen H, Rosenbach M, Shei GJ, Singer II, Tian M, West S, White V, Xie J, Proia RL, Mandala S. (2004). Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 309:758-768.
9. Gergely P, Wallström E, Nuesslein-Hildesheim B, Bruns C, Zécri F, Cooke N, Traebert M, Tuntland T, Rosenberg M, Saltzman M. (2009). Phase I study with selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. Mult Scler 15:S31-S150.
10. Gerlowski LE, Jain RK. (1983). Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72:1103-1127.
11. Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
12. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533.
13. Keldenich J. (2004). Prediction of human clearance (CL) and volume of distribution (VD). Drug Discov Today Technol 1:389-395.
14. Lavé T, Coassolo P, Reigner B. (1999). Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet 36:211-231.
15. Lin JH, Yamazaki M. (2003). Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42:59-98.
16. Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895.
17. Marsolais D, Rosen H. (2009). Chemical modulators of sphingosine- 1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov 8:297-307.
18. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. (2004). Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355-360.
19. Meno-Tetang GM, Lowe PJ. (2005). On the prediction of the human response: a recycled mechanistic pharmacokinetic/ pharmacodynamic approach. Basic Clin Pharmacol Toxicol 96:182-192.
20. Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P, Jusko WJ. (2006). Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 34:1480-1487.
21. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N, Rosen H. (2004). Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279:13839-13848.
22. Skerjanec A, Tedesco H, Neumayer HH, Cole E, Budde K, Hsu CH, Schmouder R. (2005). FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposureresponse relationship. J Clin Pharmacol 45:1268-1278.
23. Slayter KL, Ludwig EA, Lew KH, Middleton E Jr, Ferry JJ, Jusko WJ. (1996). Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 59:312-321.
24. Smith DA, Di L, Kerns EH. (2010). The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9:929-939.
25. Summerfield S, Jeffrey P. (2009). Discovery DMPK: changing paradigms in the eighties, nineties and noughties. Expert Opin Drug Discov 4:207-218.
26. Tran TT, Mittal A, Gales T, Maleeff B, Aldinger T, Polli JW, Ayrton A, Ellens H, Bentz J. (2004). Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. J Pharm Sci 93:2108-2123.
27. van Der Lee MM, Bras M, van Koppen CJ, Zaman GJ. (2008). ?-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1. J Biomol Screen 13:986-998.
28. Wei SH, Rosen H, Matheu MP, Sanna MG, Wang SK, Jo E, Wong CH, Parker I, Cahalan MD. (2005). Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 6:1228-1235.